Open AccessDebate: Should mesalamine be used in Crohn's disease? Comments and conclusions
Author(s) -
Kamm Michael A
Publication year - 2005
Publication title -
inflammatory bowel diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1097/01.mib.0000160744.32396.02
Subject(s) - ulcerative colitis , crohn's disease , medicine , disease , gastroenterology , crohn disease , inflammatory bowel disease , intensive care medicine
Mesalamine has a well‐established role in the management of ulcerative colitis. However, its role in the management of Crohn's disease (CD) is less clear. Studies evaluating its therapeutic value in CD have produced both positive and negative results. Meta‐analyses have not clarified the situation, possibly because they have combined studies of different design. This debate critically examines the evidence for and against the use of mesalamine in CD.